No Data
No Data
Innovative drug concept rises against the market, with Innovent Bio (01801) increasing by 3.85%. The State Drug Administration has agreed to carry out related evaluation and approval pilots in Beijing and Shanghai.
Jingu Wealth News | Innovative drug concept rises against the trend, with Remegen (09995) up 6.15%, Innovent Bio (01801) up 3.85%, Akeso (09926) up 2.84%, Hutchmed (China) (00013) up 2.55%, Frontage (01521) up 2.41%, Innocare (09969) up 1.96%, Canbridge Life Sciences-B (02162) up 1.86%, and BeiGene (06160) up 1.21%. The National Medical Products Administration has approved the pilot program for optimizing clinical trial evaluation and approval of innovative drugs in Beijing and Shanghai after review.
Hong Kong stock concept tracking | National Medical Products Administration approved the pilot program of optimizing the clinical trial review and approval of innovative drugs in Peking and Shanghai, and innovative drugs are expected to outperform other s
The pharmaceutical industry is expected to see overall year-on-year improvement and quarter-on-quarter growth in performance in the second half of the year.
NICE Recommends BeiGene's MZL Tablet for NHS Use
Beigene obtained 0.3635 million shares of common stock due to restricted stock units.
Beigene (06160) announced that on July 31, 2024, 0.3635 million ordinary shares were issued due to the attribution of restricted share units granted under the equity plan (excluding the directors of the company).
Beigene (06160.HK) received 0.3635 million shares due to restricted share unit ownership.
On August 1st, Gelonhui reported that Beigene(06160.HK) issued 0.3635 million ordinary shares on July 31, 2024, due to the attribution of restricted share units granted under the equity incentive plan (excluding company directors).
Beigene was attributed to the issuance of 0.1363 million restricted share units.
Beigene (06160) announced that on July 30, 2024, 0.1363 million ordinary shares were issued due to the attribution of restricted share units granted under the equity plan, excluding company directors.
No Data